Please ensure Javascript is enabled for purposes of website accessibility

Here's Why ShockWave Medical Jumped for a Second Straight Day

By Brian Orelli, PhD – Updated May 10, 2019 at 4:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The medical device maker is on fire.

What happened

Shares of ShockWave Medical (SWAV 2.37%) continued higher today, up 17% going into the closing bell. All told, shares are up 33% in the two days following the release of the medical device company's first-quarter earnings report.

So what

Going back just a little further to the company's initial public offering in March, ShockWave Medical's shares are up a whopping 335%.

You read that right: Shares have quadrupled in a little over two months.

While that's great news for investors, the company seems to have left money on the table during the IPO. A higher initial valuation would have allowed ShockWave to raise additional capital, which it certainly could use as it moves into coronary patients. Alternatively, a higher valuation at the IPO would have allowed the company to raise the same amount by selling fewer shares, thereby creating less dilution.

Doctor talking to a patient in an exam room

Image source: Getty Images.

Now what

It's hard to know how high shares of ShockWave can go. Based on management's guidance for 2019 revenue in the range of $33 million to $36 million, the company certainly looks extremely expensive. Using the forward estimate and today's price, it's a price-to-sales ratio around 45.

But investors are clearly looking beyond this year -- as they should -- into a potential launch of the C2 Coronary IVL in the U.S. in 2021. Between now and then, investors will get to see how the C2 sells in Europe and the company can grow sales of its currently available M5 IVL device in peripheral artery disease.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends ShockWave Medical. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ShockWave Medical Stock Quote
ShockWave Medical
SWAV
$260.83 (2.37%) $6.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.